Research Analysts Set Expectations for COGT Q1 Earnings

Key Points

• HC Wainwright expects Cogent Biosciences to report a Q1 2027 loss of $0.50 per share and forecasts a full-year 2027 loss of $1.28 per share. The firm maintains a Buy rating and a $55 price target.
• Cogent’s latest quarterly results beat expectations, with an EPS loss of $0.52 versus the consensus estimate of $0.55. Analysts overall give the stock a Moderate Buy rating with a consensus price target of $49.40.
• Shares opened at $36.85 after falling 1.5%, while institutional ownership increased among investors including AQR Capital Management, Goldman Sachs, and Jane Street during the first quarter.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for Cogent Biosciences in a note issued to investors on Wednesday, August 19th. HC Wainwright analyst R. Burns expects that the technology company will post earnings per share of ($0.50) for the quarter. HC Wainwright has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Cogent Biosciences' Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($1.28) EPS.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.03.

COGT has been the topic of a number of other research reports. Wedbush restated an "outperform" rating and set a $55.00 price target on shares of Cogent Biosciences in a research note on Friday, May 29th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Piper Sandler raised their price target on shares of Cogent Biosciences from $52.00 to $55.00 and gave the company an "overweight" rating in a research report on Monday. Finally, Guggenheim lifted their price objective on shares of Cogent Biosciences from $45.00 to $52.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $49.40.

Cogent Biosciences Trading Down 1.5%

NASDAQ:COGT opened at $36.85 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.57 and a current ratio of 13.57. The firm has a market cap of $6.39 billion, a P/E ratio of -17.06 and a beta of 0.38. Cogent Biosciences has a one year low of $11.53 and a one year high of $43.73. The firm has a 50-day simple moving average of $38.36 and a 200-day simple moving average of $36.63.

Institutional Trading of Cogent Biosciences

Several institutional investors have recently added to or reduced their stakes in COGT. AQR Capital Management LLC lifted its holdings in Cogent Biosciences by 482.6% during the 1st quarter. AQR Capital Management LLC now owns 160,767 shares of the technology company's stock worth $963,000 after buying an additional 133,174 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Cogent Biosciences by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company's stock worth $377,000 after buying an additional 3,693 shares during the period. Goldman Sachs Group Inc. increased its stake in Cogent Biosciences by 14.3% in the first quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company's stock valued at $5,924,000 after purchasing an additional 124,069 shares during the period. Jane Street Group LLC raised its stake in shares of Cogent Biosciences by 66.2% during the first quarter. Jane Street Group LLC now owns 123,822 shares of the technology company's stock worth $742,000 after purchasing an additional 49,338 shares during the last quarter. Finally, Strs Ohio purchased a new position in Cogent Biosciences during the first quarter worth about $36,000.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source